Pharmacological management of chemotherapy-induced nausea and vomiting in children with cancer

Journal of Chemotherapy

Volumn 21, Issue 6, 2009, Pages 605-610

  Cefalo, M G ^a   Ruggiero, Antonio ^a   Maurizi, P ^a   Attina G ^a   Arlotta, A ^a   Riccardi, R ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Antiemetic agents; Chemotherapy; Children; Nausea; Vomiting

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; BUTYROPHENONE DERIVATIVE; CARMUSTINE; CHLORAL HYDRATE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GRANISETRON; HISTAMINE H1 RECEPTOR; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR; ONDANSETRON; PALONOSETRON; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; SCOPOLAMINE; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN ANTAGONIST; SUBSTANCE P; TACHYKININ RECEPTOR; TROPISETRON; UNINDEXED DRUG; ANTIEMETIC AGENT;

AMINOTRANSFERASE BLOOD LEVEL; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL ASSESSMENT; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CHOICE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; NAUSEA; OCULOGYRIC CRISIS; OUTCOME ASSESSMENT; PARKINSONISM; PATHOPHYSIOLOGY; RATING SCALE; REVIEW; SIDE EFFECT; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; FEMALE; MALE; NEOPLASM; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; NAUSEA; NEOPLASMS; VOMITING;

EID: 77649293779     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.6.605     Document Type: Review

References (47)

1. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs. 2009; 69(5): 515-33
2. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. May 29, 2009. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-v40
3. Warr DG. Chemotherapy- and cancer -related nausea and vomiting. Curr Oncol. 2008; 15 (Supplement 1): S4-9
4. Herrstedt J, Koeller JM, Roila F, Hesketh PJ, Warr D, Rittenberg C et al. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005; 13(2): 97-103.
5. Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LH et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005; 13(2): 104-08.
6. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2005; 13:117-121
7. Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP et al. Chemotherapy-Induced Nausea and Vomiting. Clin J Oncol Nurs. 2002; 6 (2): 94-102
8. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358(23):2482-94.
9. Yamada T, Tanaka N, Yokoi K, Ishikawa N, Seya T, Horiba K et al. Substance P and anticancer drug-induced emesis. Gan To Kagaku Ryoho. 2007; 34(6): 903-06
10. WHO handbook for reporting results of Cancer Treatment. WHO offset publication No 48 Neoplasma. 1980; 20: 37-46
11. NCI Common Toxicity Criteria. National Cancer Institute, Division of Cancer Treatment. 1988
12. Franklin HR, Simonetti GPC, Dubbelman AC, ten Bokkel Huinink WW, Taal BG, Wigbout G et al. Toxicity grading systems. Ann Oncol. 1994; 5: 113-17
13. Lohr L. Chemotherapy - induced nausea and vomiting. Cancer J 2008; 14(2): 85-93
14. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007; 12(9): 1143-50
15. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G et al. A proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15: 103-109
16. Multinational Association of Supportive Care in Cancer - Antiemetic Guidelines-. March 2008. http://data.memberclicks.com/site/mascc/MASCC- Guidelines-Update.pdf
17. Relling MV, Mulhern RK, Fairclough D, Baker D, Pui CH. Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. J Pediatr. 1993; 123:811-16
18. Nahata MC, Ford C, Ruymann FB. Pharmacokinetics and safety of prochlorperazine in paediatric patients receiving cancer chemotherapy. J Clin Pharm Ther. 1992; 17: 121-23
19. Howrie DL, Felix C, Wollman M, Juhl RP, Blatt J. Metoclopramide as an antiemetic agent in pediatric oncology patients. Drug Intell Clin Pharm. 1986; 20(2):122-4
20. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008; 5(1):32-43
21. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007; 61(2):162-75
22. Roila F, Feyer P, Maranzano E, Olver I, Clark-Snow R, Warr D et al. Antiemetics in children receiving chemotherapy. Support Care Cancer. 2005; 13(2):129-31
23. Culy CR, Bhana N, Plosker GL. Ondansetron: a review of its use as an antiemetic in children. Paediatr Drugs. 2001; 3(6):441-79
24. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004; 9(6):673-86.
25. Cappelli C, Ragni G, De Pasquale MD, Gonfiantini M, Russo D, Clerico A. Tropisetron: optimal dosage for children in prevention of chemotherapy-induced vomiting. Pediatr Blood Cancer. 2005; 45(1):48-53
26. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17:1441-9.
27. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-24
28. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009; 10(4): 629-44
29. Hasler SB, Hirt A, Ridolfi Luethy A, Leibundgut KK, Ammann RA. Safety of ondansetron loading doses in children with cancer. Support Care Cancer. 2008; 16(5):469-75.
30. Hickock JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 anti-emetics. Cancer. 2003; 97: 2880-86
31. Girish C, Manikandan S. Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Indian J Cancer. 2007; 44(1):25-30
32. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001; 19: 1759-67
33. Poli-Bigelli S, Rodriguez-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hippie A et al. Addition of the neurokinin-1 receptor antagonist aprepitant to standard anti-emetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003; 97: 3090-98
34. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, O'Brien M, Schellens JH et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist L-754,030, with ondasentron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001; 37: 835-42
35. Sarcev T, Secen N, Zaric B, Milovancev A. Aprepitant - where do we stand in the control of chemotherapy-induced nausea and vomiting? J BUON. 2008; 13(3): 333-39
36. de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M et al. The oral NK-1 antagonist, aprepitant, given with standard anti-emetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analyses of two randomized, placebo-controlled Phase III clinical trials. Eur J Cancer. 2004; 40: 403-10
37. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007; 101(3): 143-50
38. Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy -induced nausea and vomiting. Expert Rev Anticancer Ther. 2004; 4(5): 715-24
39. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009; 52(2):242-7
40. Dupuis LL, Lingertat-Walsh K, Walker SE. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer. 2009; 17(6):701-6
41. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007; 18(2): 233-40
42. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology. 2007; 21(8): 946-53
43. Davis M, Maida V, Daeninck P, Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007; 15: 63-71
44. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol. 2007;5(5 Suppl 3):1-9
45. Reindl TK, Geilen W, Hartmann R, Wiebelitz KR, Kan G, Wilhelm I et al. Acupunture against chemotherapy-induced nausea and vomiting in pediatric oncology. Interim results of a multicenter crossover study. Support Care Cancer. 2006; 14: 172-76
46. Bao T. Use of acupuncture in the control of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2009; 7(5):606-12
47. Richardson J, Smith JE, McCall G, Richardson A, Pilkington K, Kirsch I. Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence. Eur J Cancer Care. 2007; 16(5):402-12.